TD Asset Management Inc Sells 2,387 Shares of Humana Inc. (NYSE:HUM)

Key Points

• TD Asset Management Inc reduced its stake in Humana Inc. by 4.0%, selling 2,387 shares and ending with 57,959 shares valued at $15.3 million.
• Wall Street analysts have various price targets for Humana, with Wells Fargo setting a target at $348.00, while the consensus price target stands at $282.43.
• Humana reported earnings of $6.27 EPS for the last quarter, missing estimates by ($0.05), but achieved a 9.6% year-over-year revenue increase to $32.39 billion.

TD Asset Management Inc lessened its position in Humana Inc. (NYSE:HUM - Free Report) by 4.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,959 shares of the insurance provider's stock after selling 2,387 shares during the quarter. TD Asset Management Inc's holdings in Humana were worth $15,336,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of HUM. Deutsche Bank AG grew its position in Humana by 18.2% in the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock worth $160,185,000 after purchasing an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Humana during the 1st quarter valued at about $1,309,000. Fred Alger Management LLC acquired a new stake in shares of Humana during the 4th quarter valued at about $451,000. Clearline Capital LP acquired a new stake in shares of Humana during the 4th quarter valued at about $1,102,000. Finally, Envestnet Asset Management Inc. boosted its position in shares of Humana by 2.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock valued at $33,256,000 after acquiring an additional 2,950 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HUM. Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a research report on Thursday, May 1st. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Robert W. Baird decreased their target price on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Bank of America decreased their target price on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research report on Tuesday, June 17th. Finally, Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Sixteen analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of "Hold" and an average price target of $281.62.

Humana Price Performance

Shares of HUM stock traded down $2.68 during trading hours on Friday, reaching $247.19. 1,756,006 shares of the company were exchanged, compared to its average volume of 1,854,830. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $382.72. The stock's fifty day moving average is $235.09 and its two-hundred day moving average is $255.24. The company has a market cap of $29.73 billion, a price-to-earnings ratio of 18.97, a P/E/G ratio of 1.66 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%. The company had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. During the same quarter in the previous year, the company posted $6.96 earnings per share. Humana's revenue for the quarter was up 9.6% on a year-over-year basis. Sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.